Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
See Attems and Jellinger (doi:10.1093/brain/awx360) for a scientific commentary on this article.Cognitive changes occurring throughout the pathogenesis of neurodegenerative diseases are directly linked to synaptic loss. We used in-depth proteomics to compare 32 post-mortem human brains in the prefrontal cortex of prospectively followed patients with Alzheimer's disease, Parkinson's disease with dementia, dementia with Lewy bodies and older adults without dementia. In total, we identified 10 325 proteins, 851 of which were synaptic proteins. Levels of 25 synaptic proteins were significantly altered in the various dementia groups. Significant loss of SNAP47, GAP43, SYBU (syntabulin), LRFN2, SV2C, SYT2 (synaptotagmin 2), GRIA3 and GRIA4 were further validated on a larger cohort comprised of 92 brain samples using ELISA or western blot. Cognitive impairment before death and rate of cognitive decline significantly correlated with loss of SNAP47, SYBU, LRFN2, SV2C and GRIA3 proteins. Besides differentiating Parkinson's disease dementia, dementia with Lewy bodies, and Alzheimer's disease from controls with high sensitivity and specificity, synaptic proteins also reliably discriminated Parkinson's disease dementia from Alzheimer's disease patients. Our results suggest that these particular synaptic proteins have an important predictive and discriminative molecular fingerprint in neurodegenerative diseases and could be a potential target for early disease intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both conditions, these altered functions largely originate from synaptic dysfunction relating to altered synaptic proteomes31,32.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies of postmortem human brains have found the significant association between cognitive decline and the loss of synaptic proteins in PFC, such as SNAP25, SNAP47, SV2C, SYT2 and GRIA3 253,254”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [253]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Synapses are the hub of neuron communications, and their degeneration is widely observed across multiple neurodegenerative diseases and increasingly recognized as a central cause of dementia 2,4,5,8,16 .”
From NAD+ hydrolase Sarm1 is a key driver of synapse degeneration and memory loss in Alzheimer’s disease (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“suggesting that these PFC synaptic markers are predictive molecular fingerprint for neurodegenerative diseases”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [253]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Cognitive data were available for most patients and consisted of the last Mini-Mental State Examination (MMSE) scores, assessed in most cases within 1–2 years before death (Folstein et al., 1975) and MMSE decline calculated as average decline over a period of clinical observation of 8–10 years.”
MethodSystematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 2×
“, 2010), a characteristic feature in Alzheimer’s disease (Terry et al., 1991; Honer, 2003) and increasing attention is now being devoted to their role in synucleinopathies (Aarsland et al.”
BackgroundThe molecular biology of memory storage: a dialogue between genes and synapses
Kandel, E. R. (2001) · Science · doi:10.1126/science.1067020 · Cited by 3,917
Cited by
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Rodent models for Alzheimer disease
Götz, J., Bodea, L.-G., & Goedert, M. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0054-8 · Cited by 394
Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
Bridi, J. C., & Hirth, F. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00080 · Cited by 378
“Studies investigating levels of synaptic proteins belonging to the SNARE complex in PD, PD with dementia (PDD) and DLB post-mortem samples also reported misregulation of proteins belonging to the SNARE complex (Kramer and Schulz-Schaeffer, 2007; Dijkstra et al., 2015; Bereczki et al., 2016, 2018).”
BackgroundHigginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9360 · Cited by 367
Higginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Johnson, E. C. B., Hajjar, I., Lah, J. J., Levey, A. I., et al. (2019) · doi:10.1101/806752 · Cited by 367
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
“10 CONFIDENTIAL Other synaptic proteins including SNAP25, RAB3A, GAP43, AMPA receptor subunits, and a number of other proteins also show promise as CSF biomarkers of synaptic damage and loss (24,25,124,125).”
BackgroundYan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
“…found a signi fi cant association between cognitive decline and the loss of synaptic proteins in PFC, such as SNAP25, SNAP47, SV2C, SYT2, and GRIA3 [253, 254], suggesting that these PFC synaptic markers are predictive molecular fi ngerprint for neurodegenerative diseases, and understanding the…”
BackgroundDEqMS: A Method for Accurate Variance Estimation in Differential Protein Expression Analysis
Zhu, Y., Orre, L. M., Zhou Tran, Y., Mermelekas, G., Johansson, H. J., Malyutina, A., Anders, S., & Lehtiö, J. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001646 · Cited by 289
“Data Set D6 - Clinical Proteomics Human Brain—Search results of this data was downloaded from ProteomeXchange with identifier PXD006122 associated with a previous study (25).”
MethodSelf-citationDementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
Shi, H., Ge, X., Ma, X., Zheng, M., Cui, X., Pan, W., Zheng, P., Yang, X., Zhang, P., Hu, M., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01172-0 · Cited by 247
“Furthermore, GAP43 and SV2C, synaptic markers of cognitive decline in the brains of dementia patients [18], were revealed here to interact with CaMKIId and were decreased in the hippocampus of FD mice.”
BackgroundMorris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
“For a recent promising example of one attempt to separate subclasses of dementia using synaptic markers see [20].”
BackgroundWingo, A. P., Dammer, E. B., Breen, M. S., Logsdon, B. A., Duong, D. M., Troncosco, J. C., Thambisetty, M., Beach, T. G., Serrano, G. E., Reiman, E. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09613-z · Cited by 211
Reverse engineering Lewy bodies: how far have we come and how far can we go?
Fares, M. B., Jagannath, S., & Lashuel, H. A. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-00416-6 · Cited by 206
Hallacli, E., Kayatekin, C., Nazeen, S., Wang, X. H., Sheinkopf, Z., Sathyakumar, S., Sarkar, S., Jiang, X., Dong, X., Di Maio, R., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.008 · Cited by 169
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
McGrowder, D. A., Miller, F., Vaz, K., Nwokocha, C., Wilson-Clarke, C., Anderson-Cross, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 167
Mallach, A., Zielonka, M., van Lieshout, V., An, Y., Khoo, J. H., Vanheusden, M., Chen, W.-T., Moechars, D., Arancibia-Carcamo, I. L., Fiers, M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114216 · Cited by 135
“37,39 Furthermore, in Stereo-seq, where we had more statistical power and a wider selection of genes, we found that other neuronal functions, such as ‘‘regulation of membrane potential,’’ were disrupted in plaque niches with more microglia (Figure S3B).”
The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00351 · Cited by 112
Agliardi, C., Meloni, M., Guerini, F. R., Zanzottera, M., Bolognesi, E., Baglio, F., & Clerici, M. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105185 · Cited by 109
Luca, C. D., Colangelo, A. M., Virtuoso, A., Alberghina, L., & Papa, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041539 · Cited by 112
“Dysfunctional levels of NTs, as well as SNAP‐25, Syntaxin‐1, Syp, PSD‐95, MAGUK, and SHANK proteins, are involved in neurodegenerative diseases, such as Alzheimerʹs disease (AD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB) [59].”
Backgroundα‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
van Steenoven, I., Majbour, N. K., Vaikath, N. N., Berendse, H. W., van der Flier, W. M., van de Berg, W. D. J., Teunissen, C. E., Lemstra, A. W., & El‐Agnaf, O. M. A. (2018) · Movement Disorders · doi:10.1002/mds.111 · Cited by 104
“0 (62-99)(6) 45 (35-57) t-α-syn (ng/mL),(3) mean ± SD 1.”
Zhou, M., Haque, R. U., Dammer, E. B., Duong, D. M., Ping, L., Johnson, E. C. B., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09285-8 · Cited by 92
Calcium Sensors in Neuronal Function and Dysfunction
Burgoyne, R. D., Helassa, N., McCue, H. V., & Haynes, L. P. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035154 · Cited by 94
“A potential linkage of SYT2 to defects of central nervous function comes from the observation that SYT2 protein levels were reduced in the brains of patients who had dementias (Bereczki et al. 2018).”
BackgroundKádková, A., Radecke, J., & Sørensen, J. B. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.09.020 · Cited by 105
Longhena, F., Faustini, G., Spillantini, M. G., & Bellucci, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010141 · Cited by 93
van Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00388-2 · Cited by 83
A Novel Targeted and High‐Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease
Yang, H., Mu, W., Wei, D., Zhang, Y., Duan, Y., Gao, J., Gong, X., Wang, H., Wu, X., Tao, H., et al. (2020) · Advanced Science · doi:10.1002/advs.201902906 · Cited by 79
Identification of Conserved Proteomic Networks in Neurodegenerative Dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Dai, J., Lah, J. J., Johnson, E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107807 · Cited by 78
“…in neurodegenerative dementia cases (AD, FTD-TDP), and not other neurodegenerative conditions suggesting that this module may contribute to shared pathogenic pathways related to cerebral cortical dysfunction (Bereczki et al., 2018; Bigio et al., 2001; Clare et al., 2010; Hassan et al., 2011).”
BackgroundIdentification of conserved proteomic networks in neurodegenerative dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Lah, J. J., Johnson, E. E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2019) · doi:10.1101/825802 · Cited by 78
TGF-β Signaling: A Therapeutic Target to Reinstate Regenerative Plasticity in Vascular Dementia?
Kandasamy, M., Anusuyadevi, M., Aigner, K. M., Unger, M. S., Kniewallner, K. M., Sousa, D. M. B. D., Altendorfer, B., Mrowetz, H., Bogdahn, U., & Aigner, L. (2020) · Aging and disease · doi:10.14336/ad.2020.0222 · Cited by 77
“Synaptophysin, a presynaptic vesicle-specific protein is considered as a marker of synaptic integrity [197-199].”
BackgroundProteomics of neurodegenerative diseases: analysis of human post‐mortem brain
Li, K. W., Ganz, A. B., & Smit, A. B. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14603 · Cited by 78
“Bereczki and colleagues compared the prefrontal cortex proteomes from 32 cases (eight controls, eight PDD, seven DLB and nine AD) (Bereczki et al. 2018).”
BackgroundWilliams, J. B., Cao, Q., & Yan, Z. (2021) · Brain Communications · doi:10.1093/braincomms/fcab123 · Cited by 71
“RAB3A is a small GTP-binding protein regulating synaptic vesicle exocytosis,(47) and is reduced in the brain of patients with Alzheimer’s disease and other dementia.(37,48) The loss of genes in M1 and M8 may directly underlie synaptic dysfunction in Alzheimer’s disease, the best correlate of cognitive impairment.”
BackgroundQuantitative proteomic analysis of the frontal cortex in Alzheimer’s disease
Sathe, G., Albert, M., Darrow, J., Saito, A., Troncoso, J., Pandey, A., & Moghekar, A. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15116 · Cited by 65
“Although the role of the RALA is not clear in AD pathology, association of other Small GTPases has been previously described in AD (Besga et al., 2017; Qu et al., 2019).”
BackgroundTorres, C. A. M., Wassouf, Z., Zafar, F., Sastre, D., Outeiro, T. F., & Schüle, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165724 · Cited by 66
“Synaptic deficits in LBD have been attributed to synaptic accumulation of α-syn at presynaptic terminals affecting neurotransmitter release [261-263].”
BackgroundFranzmeier, N., Dehsarvi, A., Steward, A., Biel, D., Dewenter, A., Roemer, S. N., Wagner, F., Groß, M., Brendel, M., Moscoso, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44374-w · Cited by 68
Ghrelin in Alzheimer’s disease: Pathologic roles and therapeutic implications
Jeon, S. G., Hong, S. B., Nam, Y., Tae, J., Yoo, A., Song, E. J., Kim, K. I., Lee, D., Park, J., Lee, S. M., et al. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100945 · Cited by 58
Platelet biomarkers for a descending cognitive function: A proteomic approach
Yu, H., Liu, Y., He, B., He, T., Chen, C., He, J., Yang, X., & Wang, J. (2021) · Aging Cell · doi:10.1111/acel.13358 · Cited by 63
Nilsson, J., Constantinescu, J., Nellgård, B., Jakobsson, P., Brum, W. S., Gobom, J., Forsgren, L., Dalla, K., Constantinescu, R., Zetterberg, H., et al. (2022) · Movement Disorders · doi:10.1002/mds.29287 · Cited by 64
“However, a proteome study in postmortem human brain found that synaptic proteins were able to differentiate PD with dementia from controls and AD and that they associated with cognitive decline.(14) We have previously identified 15 synaptic proteins in the CSF as potential synaptic biomarkers and studied them in AD.”
BackgroundDendritic spines are lost in clusters in Alzheimer’s disease
Mijalkov, M., Volpe, G., Fernaud-Espinosa, I., DeFelipe, J., Pereira, J. B., & Merino-Serrais, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-91726-x · Cited by 55
Self-citationNeuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimer’s Disease
Eren, E., Leoutsakos, J.-M., Troncoso, J., Lyketsos, C. G., Oh, E. S., & Kapogiannis, D. (2022) · Cells · doi:10.3390/cells11030436 · Cited by 53
“Moreover, synaptic integrity-related protein biomarkers were shown to strongly correlate with cognitive deficits and decline in MMSE scores [45].”
BackgroundSherva, R., Gross, A., Mukherjee, S., Koesterer, R., Amouyel, P., Bellenguez, C., Dufouil, C., Bennett, D. A., Chibnik, L., Cruchaga, C., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12106 · Cited by 54
Key Peptides and Proteins in Alzheimer’s Disease
Penke, B., Bogár, F., Paragi, G., Gera, J., & Fülöp, L. (2019) · Current Protein & Peptide Science · doi:10.2174/1389203720666190103123434 · Cited by 49
Karyopherin abnormalities in neurodegenerative proteinopathies
Pasha, T., Zatorska, A., Sharipov, D., Rogelj, B., Hortobágyi, T., & Hirth, F. (2021) · Brain · doi:10.1093/brain/awab201 · Cited by 53
Self-citationFrigerio, I., Bouwman, M. M. A., Noordermeer, R. T. G. M. M., Podobnik, E., Popovic, M. M., Timmermans, E., Rozemüller, A. J. M., van de Berg, W. D. J., & Jonkman, L. E. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01711-w · Cited by 47
“In post-mortem brains, a loss of synaptophysin [15] and several other synaptic proteins [16] was reported in frontal, occipital and hippocampal regions in PD, and in the parietal cortex in DLB [17].”
BackgroundInfluentialSALM/Lrfn Family Synaptic Adhesion Molecules
Lie, E., Li, Y., Kim, R., & Kim, E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00105 · Cited by 43
“Lastly, recent clinical studies have additionally identified associations of SALMs with diverse neurodevelopmental disorders (Nho et al., 2015; Rautiainen et al., 2016; Thevenon et al., 2016; Farwell Hagman et al., 2017; Morimura et al., 2017; Bereczki et al., 2018).”
BackgroundVGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
van Steenoven, I., Noli, B., Cocco, C., Ferri, G., Oeckl, P., Otto, M., Koel‐Simmelink, M. J. A., Bridel, C., van der Flier, W. M., Lemstra, A. W., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194674 · Cited by 47
“Such findings support the hypothesis that synaptic dysfunction may be a nonspecific proxy for decline in multiple neurodegenerative diseases [16].”
BackgroundArc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer’s Disease
Leung, H.-W., Foo, G., & VanDongen, A. M. J. (2022) · Biomedicines · doi:10.3390/biomedicines10081946 · Cited by 46
Ross, J. M., Coppotelli, G., Branca, R. M., Kim, K. M., Lehtiö, J., Sinclair, D. A., & Olson, L. (2019) · Aging Cell · doi:10.1111/acel.13029 · Cited by 41
Self-citationAfsar, A., Castro, M. D. C. C., Soladogun, A. S., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087258 · Cited by 49
Ramos-Miguel, A., Jones, A. A., Sawada, K., Barr, A. M., Bayer, T. A., Falkai, P., Leurgans, S. E., Schneider, J. A., Bennett, D. A., & Honer, W. G. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.02.006 · Cited by 37
Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders
Hall, S., Janelidze, S., Zetterberg, H., Brix, B., Mattsson, N., Surova, Y., Blennow, K., & Hansson, O. (2019) · Movement Disorders · doi:10.1002/mds.27950 · Cited by 39
“A recent postmortem, human brain proteome study on patiens with and without dementia found that synaptic proteins, but not any individual protein, could differentiate PD with dementia (PDD) and dementia with Lewy bodies (DLB) from controls and AD and that cognitive impairment and decline in life correlated with loss o…”
BackgroundInsights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis
Haytural, H., Benfeitas, R., Schedin-Weiss, S., Bereczki, E., Rezeli, M., Unwin, R. D., Wang, X., Dammer, E. B., Johnson, E. C. B., Seyfried, N. T., et al. (2021) · Scientific Data · doi:10.1038/s41597-021-01090-8 · Cited by 36
Self-citationGibson, L. L., Ruiz, C. A., Chong, J. R., Ballard, C. G., & Aarsland, D. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001173 · Cited by 38
Self-citationReview: Clinical, neuropathological and genetic features of Lewy body dementias
Hansen, D., Ling, H., Lashley, T., Holton, J. L., & Warner, T. T. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12554 · Cited by 44
Widyaningrum, R., Burnouf, T., Nebie, O., Delila, L., & Wang, T.-J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112046 · Cited by 38
Bermejo‐Pareja, F., & del Ser, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020536 · Cited by 42
A synapsin Ⅰ cleavage fragment contributes to synaptic dysfunction in Alzheimer's disease
Meng, L., Zou, L. B., Xiong, M., Chen, J., Zhang, X., Yu, T., Li, Y., Liu, C., Chen, G., Wang, Z., et al. (2022) · Aging Cell · doi:10.1111/acel.13619 · Cited by 36
“Several synaptic proteins have been reported to be decreased in brain specimens from AD patients (Bereczki et al., 2016, 2018; Goetzl et al., 2016; Qin et al., 2004; Reddy et al., 2005).”
BackgroundWakhloo, D., Mahajani, S. U., Oberhauser, J., & Madira, A. E. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.336138 · Cited by 42
“AD progression has been previously linked to synaptic failure (Chen et al., 2019), which has been suggested as a better marker of cognitive decline than the accumulation of NTFs and Aβ plaques (Bereczki et al., 2018).”
The 2024 Report on the Human Proteome from the HUPO Human Proteome Project
Omenn, G. S., Orchard, S. E., Lane, L., Lindskog, C., Pineau, C., Overall, C. M., Budnik, B., Mudge, J. M., Packer, N. H., Weintraub, S. T., et al. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00776 · Cited by 40
Belloso-Iguerategui, A., Zamarbide, M., Merino-Galán, L., Rodríguez-Chinchilla, T., Gago, B., Santamaría, E., Fernández‐Irigoyen, J., Cotman, C. W., Prieto, G. A., Quiroga‐Varela, A., et al. (2023) · Brain · doi:10.1093/brain/awad227 · Cited by 34
Mass synaptometry: High-dimensional multi parametric assay for single synapses
Gajera, C. R., Fernandez, R., Postupna, N. O., Montine, K. S., Fox, E. J., Tebaykin, D., Angelo, M., Bendall, S. C., Keene, C. D., & Montine, T. J. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.11.008 · Cited by 34
“We deliberately assembled our SynTOF panel to validate at the single synapse level the many existing bulk tissue analyses of human synapses, including western blots, proteomics, and molecular imaging studies (Bereczki et al., 2018; Caudle et al., 2008; Datta et al., 2017; Galasko et al., 1996; Hansen et al., 1998; Jel…”
Ping, S., Qiu, X., Kyle, M. M., Hughes, K., Longo, J. A., & Zhao, L. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104561 · Cited by 34
The role of synaptic biomarkers in the spectrum of neurodegenerative diseases
Mazzucchi, S., Palermo, G., Campese, N., Galgani, A., Vecchia, A. D., Vergallo, A., Siciliano, G., Ceravolo, R., Hampel, H. J., & Baldacci, F. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1831388 · Cited by 34
Soltani, A., Chugaeva, U. Y., Ramadan, M. F., Saleh, E. A. M., Al-Hasnawi, S. S., Romero‐Parra, R. M., Alsaalamy, A. H., Mustafa, Y. F., Zamanian, M. Y., & Golmohammadi, M. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01361-3 · Cited by 34
“The aberrant function of the Gria3 gene can result in neuronal damage, presenting as cognitive impairment and epilepsy and playing a role in migraine (Gasparini et al. 2016; Bereczki et al. 2018).”
BackgroundPlatelet biomarkers identifying mild cognitive impairment in type 2 diabetes patients
Yu, H., Liu, Y., He, T., Zhang, Y., He, J., Li, M., Jiang, B., Gao, Y., Chen, C., Ke, D., et al. (2021) · Aging Cell · doi:10.1111/acel.13469 · Cited by 29
Haytural, H., Mermelekas, G., Emre, C., Nigam, S. M., Carroll, S. L., Winblad, B., Bogdanovic, N., Barthet, G., Granholm, A.-C., Orre, L. M., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001737 · Cited by 29
Self-citationInclusion of African American/Black adults in a pilot brain proteomics study of Alzheimer's disease
Stepler, K. E., Mahoney, E. R., Kofler, J., Hohman, T. J., López, O. L., & Robinson, R. A. S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105129 · Cited by 27
Yu, A., Hu, J., Fu, L., Huang, G., Deng, D., Zhang, M., Wang, Y., Shu, G., Jing, L., Li, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007230 · Cited by 36
“21 Meanwhile, LRFN2 has been shown to interact with N- methyl- D-aspartic acid (NMDAR) and cause poly-cythemia.”
BackgroundHe, J., Liu, F., Xu, T., Ma, J., Yu, H., Zhao, J., Xie, Y., Luo, L., Yang, Q., Lou, T., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115807 · Cited by 29
Function of Drosophila Synaptotagmins in membrane trafficking at synapses
Quiñones-Frías, M. C., & Littleton, J. T. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03788-9 · Cited by 28
Murphy, J., & McKernan, D. P. (2022) · Biomolecules · doi:10.3390/biom12091199 · Cited by 25
“GAP43 Reduced ↓ 20% Human Post-mortem tissue from the PFC of PDD patients ELISA [42] Rabphilin 3A Reduced ↓ Rats Nigral injection of AAv2-A53T α-syn WB [16]”
BackgroundMethodInfluentialCSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology
Cousins, K. A. Q., Arezoumandan, S., Shellikeri, S., Ohm, D., Shaw, L. M., Grossman, M., Wolk, D., McMillan, C. T., Chen-Plotkin, A., Lee, E., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201202 · Cited by 25
“Ng is a postsynaptic protein, and although both AD and αSyn are associated with synaptic dysfunction, their synaptic CSF profiles may differ.(41) Previous work has shown elevated levels of CSF Ng specific to patients with AD,(4,42) whereas studies on patients with parkinsonian disorders found decreased CSFNg,(14) hypo…”
BackgroundChatterjee, M., van Steenoven, I., Huisman, E., Oosterveld, L. P., Berendse, H. W., van der Flier, W. M., del Campo, M., Lemstra, A. W., van de Berg, W. D. J., & Teunissen, C. E. (2020) · Biomolecules · doi:10.3390/biom10081177 · Cited by 26
“To our knowledge, CSF contactin-2 levels have not been investigated in PD patients before, although a proteomics-based study found a tendency towards lower levels of contactin-2 in the post-mortem prefrontal cortex of PD patients, compared to controls [20].”
ResultGuo, M., Zhang, H., Zhang, P.-J., Liu, X., Song, L.-J., Wei, W., Wang, Y.-Y., Mu, B., Chai, Z., Yu, J., et al. (2020) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2020.04.243 · Cited by 25
“Gap43 is highly expressed in neurons, often used as a marker for synaptic reconstruction and nerve regeneration and is significantly reduced in AD (Bogdanovic et al., 2000).”
BackgroundDisrupted myelination network in the cingulate cortex of Parkinson's disease
Xie, S., Yang, J., Huang, S., Fan, Y., Xu, T., He, J., Guo, J., Ji, X., Wang, Z., Li, P., et al. (2022) · IET Systems Biology · doi:10.1049/syb2.12043 · Cited by 27
Mravinacová, S., Alanko, V., Bergström, S., Bridel, C., Pijnenburg, Y. A. L., Hagman, G., Kivipelto, M., Teunissen, C. E., Nilsson, P., Matton, A., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00705-z · Cited by 29
“An alternative approach for assessing neurodegeneration is to measure synaptic damage through levels of synaptic proteins in CSF. Synaptic damage has been widely recognized as an indicator of neurodegeneration and stands as the most prominent predictor of cognitive decline in AD [8, 9].”
BackgroundThe synaptic pathology of cognitive life
Honer, W. G., Ramos-Miguel, A., Alamri, J., Sawada, K., Barr, A. M., Schneider, J. A., & Bennett, D. A. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.3/whoner · Cited by 25
Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D., & Giau, V. V. (2020) · Diagnostics · doi:10.3390/diagnostics10050326 · Cited by 27
Bridi, J. C., Bereczki, E., Smith, S. K., Poças, G. M., Kottler, B., Domingos, P. M. D. N., Elliott, C. J. H., Aarsland, D., & Hirth, F. (2021) · Brain Communications · doi:10.1093/braincomms/fcab049 · Cited by 26
“20,40 Despite a -syn pathology being the defining feature of DLB, this disorder is often accompanied by other age-related neurodegenerative pathologies such as amyloid plaques and tau tangles 89 that may contribute to the observed phenotypes, which remains to be determined.”
InfluentialSelf-citationAsynchronous excitatory neuron development in an isogenic cortical spheroid model of Down syndrome
Li, Z., Klein, J. A., Rampam, S., Kurzion, R., Campbell, N. B., Patel, Y., Haydar, T. F., & Zeldich, E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.932384 · Cited by 24
Uras, I., Karayel‐Basar, M., Şahin, B., & Baykal, A. T. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13008 · Cited by 25
Mass spectrometry methods for analysis of extracellular matrix components in neurological diseases
Downs, M. J., Zaia, J., & Sethi, M. K. (2022) · Mass Spectrometry Reviews · doi:10.1002/mas.21792 · Cited by 27
Epigenetic regulation in the pathophysiology of Lewy body dementia
Chouliaras, L., Kumar, G. S., Thomas, A. J., Lunnon, K., Chinnery, P. F., & O'Brien, J. T. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101822 · Cited by 28
Traffic-related air pollution and genome-wide DNA methylation: A randomized, crossover trial
Du, X., Jiang, Y., Li, H., Zhang, Q., Zhu, X., Zhou, L., Wang, W., Zhang, Y., Liu, C., Niu, Y., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.157968 · Cited by 24
Ali, J., Khan, A., Park, J. S., Tahir, M., Ahmad, W., Choe, K., & Kim, M. O. (2023) · Nutrients · doi:10.3390/nu15234986 · Cited by 23
“…fi city of NMP in human subjects and its development in respect to neurodegenerative disorders related to AD and PD. addition, preclinical trials are required to investigate the specificity of NMP in human subjects and its development in respect to neurodegenerative disorders related to AD and PD.”
BackgroundSorting nexin-27 regulates AMPA receptor trafficking through the synaptic adhesion protein LRFN2
McMillan, K. J., Banks, P. J., Hellel, F. L., Carmichael, R. E., Clairfeuille, T., Evans, A. J., Heesom, K. J., Lewis, P., Collins, B. M., Bashir, Z. I., et al. (2021) · eLife · doi:10.7554/elife.59432 · Cited by 21
“A recent proteomic screen on pre-frontal post-mortem tissue also revealed that LRFN2 protein expression was significantly decreased in people with Alzheimer’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies, further highlighting the importance of LRFN2 for neuronal function (Bereczki et al.,…”
BackgroundTahir, M., Kang, M. H., Park, T. J., Ali, J., Choe, K., Park, J. S., & Kim, M. O. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1453038 · Cited by 25
Tu, H., Zhang, Z. W., Qiu, L., Lin, Y., Jiang, M. H., Chia, S., Wei, Y., Ng, A. S. L., Reynolds, R., Tan, E., et al. (2022) · BMC Neuroscience · doi:10.1186/s12868-021-00687-4 · Cited by 24
“identified a series of synaptic biomarkers, such as the presynaptic proteins SNAP47, Rab3A, GAP43, and SYBU, which were altered in cerebrospinal fluid (CSF) and brain samples in patients with PDD, DLB and Alzheimer’s disease (AD) [12, 13].”
BackgroundWen, J., Skampardoni, I., Tian, Y., Yang, Z., Cui, Y., Erus, G., Hwang, G., Varol, E., Boquet-Pujadas, A., Chand, G. B., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01412-w · Cited by 27
Enache, D., Pereira, J. B., Jelić, V., Winblad, B. G., Nilsson, P., Aarsland, D., & Bereczki, E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200498 · Cited by 24
“Wehavepreviously identifiedGluA3levelsinprefrontalcortextobeasso-ciatedwithcognitivedecline,asmeasuredbyMMSE scores(withaprospectivefollow-upofanaverage 8years)inpatientsdiagnosedwithdementiawith Lewybodies[18].”
InfluentialSelf-citationJasutkar, H. G., Wasserlein, E. M., Ishola, A. O., Litt, N. A., Staniszewski, A., Arancio, O., & Yamamoto, A. (2024) · Autophagy · doi:10.1080/15548627.2024.2368335 · Cited by 21
Wang, X., Zhang, J., Zhou, L., Xu, B., Ren, X., He, K., Nie, L., Li, X., Liu, J., Yang, X., et al. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.05.038 · Cited by 20
Hindley, N., Avila, A. S., & Henstridge, C. M. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1130198 · Cited by 22
“For example, a recent LC-MS/MS proteomics study identified synaptic markers of cognitive decline in post-mortem AD homogenates and described a correlation between the loss of certain synaptic proteins and the extent of cognitive impairment (Bereczki et al., 2018).”
BackgroundZhang, X., Zou, L. B., Meng, L., Xiong, M., Pan, L., Chen, G., Zheng, Y., Xiong, J., Wang, Z., Duong, D. M., et al. (2021) · eLife · doi:10.7554/elife.65301 · Cited by 19
Kaur, H., Minchella, P. M., Alvarez-Carbonell, D., Purandare, N., NAGAMPALLI, V., Blankenberg, D. J., Hulgan, T., Gerschenson, M., Karn, J., Aras, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512242 · Cited by 18
“Finally, levels of the leucine-rich repeat and fibronectin type-III domain-containing protein 2 (Lrfn2), which promotes neurite growth and is a marker of synaptic integrity in the brain [36], were significantly reduced in these neural-origin cells after BIC exposure (Figure 7p).”
BackgroundTranscriptomic profiling of early synucleinopathy in rats induced with preformed fibrils
Patterson, J. R., Kochmanski, J. J., Stoll, A. C., Kubik, M., Kemp, C. J., Duffy, M. F., Thompson, K. E., Howe, J. W., Cole-Strauss, A., Kuhn, N. C., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-023-00620-y · Cited by 20
“Involving priming, decreases in Rab3A have been reported in post-mortem tissue from PDD and DLB patients 59,60 , as well as synuclein overexpression models in mice 55 and rats 58 .”
Bennett, J. P., & Keeney, P. M. (2018) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180072 · Cited by 19
“GAP43 (growth associated protein 43) gene encodes a protein (Neuromodulin) that is expressed in high levels in neural growth cones and is reduced in brains from individuals with PD dementia compared to brains from individuals with AD [16].”
Weber, J. J., Haas, E., Maringer, Y., Hauser, S., Casadei, N., Chishti, A. H., Rieß, O., & Hübener‐Schmid, J. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa010 · Cited by 18
“In Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease, proteomic studies have revealed impairment of synaptic proteins, thus pointing to their predictive and therapeutic potential (44).”
BackgroundDistinct brain regional proteome changes in the rTg‐DI rat model of cerebral amyloid angiopathy
Schrader, J. M., Xu, F., & Nostrand, W. E. V. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15463 · Cited by 20
HEBP1 - An early trigger for neuronal cell death and circuit dysfunction in Alzheimer’s disease
Chua, J. J. E. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.07.005 · Cited by 19
Metadata
- Authors
- Bereczki, E., Branca, R. M., Francis, P. T., Pereira, J. B., Baek, J.-H., Hortobágyi, T., Winblad, B., Ballard, C., Lehtiö, J., & Aarsland, D.
- Affiliations
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- King's College London (GB)
- University of Debrecen (HU)
- Corresponding author
- Bereczki, Erika
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-09
- Volume
- 141
- Issue
- 2
- Pages
- 582-595
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5837272
- OpenAlex
- W2782564735
- Cited by
- 220
- References
- 71
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 31 · 2023: 25 · 2022: 29 · 2021: 32 · 2020: 36 · 2019: 21 · 2018: 17
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Alzheimerfonden
- Parkinsonfonden
- Stohnes Stiftelse
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- synaptic proteins, cognitive decline, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, prefrontal cortex, SV2C, GRIA3, synaptotagmin 2, protein biomarkers, differential diagnosis
- MeSH terms
- Aged, Aged, 80 and over, Brain, Cognition Disorders, Female, Gene Expression Regulation, Humans, Male, Membrane Proteins, Microtubule-Associated Proteins, Nerve Tissue Proteins, Neurologic Examination, Neuropsychological Tests, Synapses, Neurodegenerative Diseases, Proteomics, Intracellular Signaling Peptides and Proteins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.